在复发性或耐火性多发性骨髓瘤中,基于B细胞成熟的抗原治疗后使用talquetamab
Asis Shrestha1, Marah Alzubi2, Jawad Alrawabdeh2
1Department of Hematology/Oncology Myeloma Center Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences Little Rock Arkansas USA.
EJHaem
|June 19, 2024
概括
在talquetamab后使用双特异性抗体 (BCMA) 治疗对于复发性耐火性多发性髓瘤患者是可行的. 这项对10名患者的研究显示,中位数无进展生存时间为5.5个月.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
背景情况:
- 塔尔克塔马布已被批准用于复发性耐火性多发性骨髓瘤.
- 缺乏关于BCMA向疗法的数据.
研究的目的:
- 在talquetamab进展后评估基于BCMA的治疗结果.
- 评估这种顺序治疗策略的可行性和临床效用.
主要方法:
- 对10名多发性骨髓瘤患者的回顾性分析.
- 在治疗talquetamab后,患者接受了基于BCMA的疗法.
- 评估了随访持续时间和无进展生存期.
主要成果:
- 随访时间中位数为9.5个月.
- 无进展生存时间的中位数为5.5个月.
- 患者经历了不同程度的细胞因子释放综合征和神经毒性.
结论:
- 用talquetamab进行连续治疗,然后以BCMA为基础的疗法是可行的.
- 这种方法可以被认为是符合条件的患者临床上适用的.
相关概念视频
Tumor Immunotherapy
511
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
511
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
T Cell Activation and Clonal Selection
701
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
701
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

